Goldman Sachs’s Jazz Pharmaceuticals JAZZ Stock Holding History

Goldman Sachs’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,400	Closed	-$1.6M	–	6751
2025 Q4	$1.6M	Buy	+9,400	New	+$1.44M	﹤0.01%	4777
2018 Q3	–	Sell	-50,000	Closed	-$8.62M	–	5688
2018 Q2	$8.62M	Buy	+50,000	New	+$8.17M	﹤0.01%	2522
2017 Q3	–	Sell	-88,200	Closed	-$13.7M	–	6755
2017 Q2	$13.7M	Buy	88,200 +65,300	+285%	+$9.99M	﹤0.01%	2259
2017 Q1	$3.32M	Buy	+22,900	New	+$2.98M	﹤0.01%	3289
2016 Q2	–	Sell	-5,000	Closed	-$653K	–	7137
2016 Q1	$653K	Buy	+5,000	New	+$622K	﹤0.01%	4475
2015 Q1	–	Sell	-11,300	Closed	-$1.85M	–	7188
2014 Q4	$1.85M	Buy	+11,300	New	+$1.88M	﹤0.01%	3921
2014 Q3	–	Sell	-86,000	Closed	-$12.6M	–	7183
2014 Q2	$12.6M	Buy	+86,000	New	+$11.9M	﹤0.01%	2184
2013 Q4	–	Sell	-50,000	Closed	-$4.6M	–	6730
2013 Q3	$4.6M	Sell	50,000 -20,000	-29%	-$1.61M	﹤0.01%	3017
2013 Q2	$4.81M	Buy	+70,000	New	+$4.28M	﹤0.01%	2785

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Goldman Sachs's JAZZ Position: Q1 2026 in Review

Goldman Sachs increased its Jazz Pharmaceuticals (JAZZ) stake by 43% in Q1 2026, buying an estimated $13.3M and bringing the position to 250,321 shares worth $47.3M. The position accounts for 0.01% of the portfolio, ranked #1616.

Goldman Sachs first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $167M in Q4 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Goldman Sachs held 250,321 shares of Jazz Pharmaceuticals worth $47.3M as of Q1 2026.
Goldman Sachs bought 75,844 Jazz Pharmaceuticals shares in Q1 2026, an estimated $13.3M.
Jazz Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1616 holding.
Goldman Sachs first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Jazz Pharmaceuticals position peaked at $167M in Q4 2021.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.